Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1297
1029
mi
from 98109
Aurora, CO
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1297
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10172
1067
mi
from 98109
Colorado Springs, CO
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10172
1067
mi
from 98109
Colorado Springs, CO
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10133
1020
mi
from 98109
Denver, CO
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10133
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 038
1024
mi
from 98109
Englewood, CO
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 038
1024
mi
from 98109
Englewood, CO
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 008
2432
mi
from 98109
New Haven, CT
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 008
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13071
2412
mi
from 98109
Stamford, CT
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13071
2412
mi
from 98109
Stamford, CT
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12299
2453
mi
from 98109
Gainesville, FL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12299
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10064
2527
mi
from 98109
Ormond Beach, FL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10064
2527
mi
from 98109
Ormond Beach, FL
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12995
2525
mi
from 98109
Saint Petersburg, FL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12995
2525
mi
from 98109
Saint Petersburg, FL
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10765
2299
mi
from 98109
Augusta, GA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10765
2299
mi
from 98109
Augusta, GA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10111
2207
mi
from 98109
Columbus, GA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10111
2207
mi
from 98109
Columbus, GA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2404
mi
from 98109
Savannah, GA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2404
mi
from 98109
Savannah, GA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
1733
mi
from 98109
Chicago, IL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 098
1902
mi
from 98109
Ann Arbor, MI
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 098
1902
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 60
873
mi
from 98109
Las Vegas, NV
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 60
873
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13578
2392
mi
from 98109
Lebanon, NH
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13578
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13769
2383
mi
from 98109
Princeton, NJ
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13769
2383
mi
from 98109
Princeton, NJ
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1184
mi
from 98109
Albuquerque, NM
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13576
2111
mi
from 98109
Amherst, NY
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13576
2111
mi
from 98109
Amherst, NY
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
2401
mi
from 98109
New York, NY
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2361
mi
from 98109
Raleigh, NC
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2361
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11
2020
mi
from 98109
Cleveland, OH
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10183
2373
mi
from 98109
Philadelphia, PA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10183
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 46
2444
mi
from 98109
Virginia Beach, VA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 46
2444
mi
from 98109
Virginia Beach, VA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 78120
mi
from 98109
Auchenflower,
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 78120
mi
from 98109
Auchenflower,
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13181
947
mi
from 98109
Canoga Park, CA
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13181
947
mi
from 98109
Canoga Park, CA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
2527
mi
from 98109
Tampa, FL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13839
2281
mi
from 98109
Salisbury, NC
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13839
2281
mi
from 98109
Salisbury, NC
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13841
1884
mi
from 98109
Richmond, TX
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13841
1884
mi
from 98109
Richmond, TX
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 34
1116
mi
from 98109
Phoenix, AZ
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 34
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10269
2547
mi
from 98109
Orlando, FL
A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10269
2547
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
Investigating the Efficacy of Using Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department: A Prospective Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
OhioHealth Doctors Hospital
2008
mi
from 98109
Columbus, OH
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
Investigating the Efficacy of Using Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department: A Prospective Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
OhioHealth Doctors Hospital
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Migraine Prevention Using ActiPatch
Migraine Prevention Using Pulsed Shortwave Therapy
Status: Enrolling
Updated:  12/31/1969
Eppley Group
1862
mi
from 98109
Indianapolis, IN
Migraine Prevention Using ActiPatch
Migraine Prevention Using Pulsed Shortwave Therapy
Status: Enrolling
Updated: 12/31/1969
Eppley Group
1862
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics
Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis School of Medicine
1718
mi
from 98109
Saint Louis, MO
Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics
Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis School of Medicine
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
1114
mi
from 98109
Scottsdale, AZ
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
1114
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Neurology Research Institute
2692
mi
from 98109
West Palm Beach, FL
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Neurology Research Institute
2692
mi
from 98109
West Palm Beach, FL
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Diamond Headache Clinic
1730
mi
from 98109
Chicago, IL
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Diamond Headache Clinic
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Michigan Headache Pain & Neurological Inst.
1905
mi
from 98109
Ann Arbor, MI
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Michigan Headache Pain & Neurological Inst.
1905
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Study Metrix Research
1698
mi
from 98109
Saint Peters, MO
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Study Metrix Research
1698
mi
from 98109
Saint Peters, MO
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
Jefferson Headache Center
2373
mi
from 98109
Philadelphia, PA
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
Jefferson Headache Center
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated:  12/31/1969
King's College London
4785
mi
from 98109
London,
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Status: Enrolling
Updated: 12/31/1969
King's College London
4785
mi
from 98109
London,
Click here to add this to my saved trials
Oral ALLOD-2 vs. Oral Sumatriptan and vs. Placebo in the Acute Treatment of Migraine With Associated Nausea (ANODYNE-2)
Single Site, Phase 2B, Randomized, Double-Blind, and Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 Versus Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)
Status: Enrolling
Updated:  12/31/1969
Annette C. Toledano MD
2726
mi
from 98109
North Miami, FL
Oral ALLOD-2 vs. Oral Sumatriptan and vs. Placebo in the Acute Treatment of Migraine With Associated Nausea (ANODYNE-2)
Single Site, Phase 2B, Randomized, Double-Blind, and Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 Versus Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)
Status: Enrolling
Updated: 12/31/1969
Annette C. Toledano MD
2726
mi
from 98109
North Miami, FL
Click here to add this to my saved trials
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device: Pilot Trial
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device: Pilot Trial
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
1113
mi
from 98109
Scottsdale, AZ
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
Status: Enrolling
Updated:  12/31/1969
University of Southern California
962
mi
from 98109
Los Angeles, CA
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
Status: Enrolling
Updated: 12/31/1969
University of Southern California
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Central Research Associates, Inc
2079
mi
from 98109
Birmingham, AL
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Central Research Associates, Inc
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Neurological Physicians of Arizona/Radiant Research Inc
1125
mi
from 98109
Gilbert, AZ
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Neurological Physicians of Arizona/Radiant Research Inc
1125
mi
from 98109
Gilbert, AZ
Click here to add this to my saved trials
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Consortium Arizona
1124
mi
from 98109
Tempe, AZ
Safety and Efficacy Study in Adult Subjects With Acute Migraines
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Consortium Arizona
1124
mi
from 98109
Tempe, AZ
Click here to add this to my saved trials